Specificity of research antibodies: “trust is good, validation is better”

We are writing you in regard to the article “Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up” by Chen et al., published 16 August 2017 in Human Pathology [1]. The authors used immunohistochemistry to analyze the expression of several signal transduction markers i n tissues samples from 672 breast cancer patients and concluded that elevated levels of phosphorylated protein phosphatase 2A (PP2A) catalytic subunit correlate with a shorter 15-year overall survival rate.
Source: Human Pathology - Category: Pathology Authors: Tags: Correspondence Source Type: research